CAR/TCR Therapies in Oncology Analytical Tool - ResearchAndMarkets.com

October 4, 2018

DUBLIN--(BUSINESS WIRE)--Oct 4, 2018--The “CAR/TCR Therapies in Oncology: Analytical Tool” report has been added to ResearchAndMarkets.com’s offering.

Your CAR/TCR Therapies in Oncology: Analytical Tool covers more than 166 companies plus partners who are today developing 494 CAR/TCR drugs where of 473 are in active developmental in cancer across 119 different targets. Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing with your own proprietary information.

Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) therapies are a game changer within cancer therapies and there is a place in history and huge recognition to both Novartis and Kite Pharma (now Gilead Sciences) for being the first companies to bring these novel therapies to market with Kymriah (tisagenlecleucel-t) and Yescarta (axicabtagene ciloleucel) respectively.

CAR/TCR Therapies in Oncology: Analytical Tool is the most up to date and comprehensive commercial pipeline review and competitive assessment available on this hot and fast moving area in immune-oncology. This unique product is truly the only one of its kind and is designed to give you a competitive edge in your CAR/TCR drug intelligence.

Your CAR/TCR Therapies in Oncology: Analytical Tool is based on two decades of proven methodology in serving clients with interest in

Target Scouting Early & Late Stage Pipeline Analysis Biomarker/Companion Diagnostic Analysis Deal & Alliance Analysis Combination Therapy Analysis Clinical Trial Results Analysis Indication Selection & Expansion Analysis First-in-Class Analysis Drug Repositioning Pipeline Analysis by Targeted Pathways

Analytical Tools transform your computer’s desktop into a high capacity workbench within your area of choice. Even before launching this tool you have already eliminated hundreds of hours of work needed to discover, process and piece together the thousands of sources that our team of oncology dedicated and highly experienced contents specialists have done on your behalf.

For more information about this report visit https://www.researchandmarkets.com/research/bwqw88/cartcr_therapies?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181004005683/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 10/04/2018 01:19 PM/DISC: 10/04/2018 01:19 PM


Update hourly